^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

    i
    Other names: PTGS2, Prostaglandin-Endoperoxide Synthase 2, Prostaglandin G/H Synthase 2, Prostaglandin-Endoperoxide Synthase 2 (Prostaglandin G/H Synthase And Cyclooxygenase), Prostaglandin H2 Synthase 2, Cyclooxygenase 2, PGH Synthase 2, PGHS-2, PHS II, COX-2, COX2, Cyclooxygenase 2b, Cyclooxygenase-2, GRIPGHS, PGG/HS, HCox-2, PHS-2
    4d
    A novel near-infrared COX-2 targeting probe for tumor and metastatic lymph node monitoring. (PubMed, Bioorg Chem)
    NY-IND showed significantly superior specificity in detecting metastatic tumor lesions including peritoneal metastasis of lung cancer and lymph node metastasis. This work presents a promising tool for real-time intraoperative visualization of tumors and metastases, advancing surgical precision and improving patient prognosis.
    Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    10d
    Developing COX-2-targeted fluorescent probes for HClO/ONOO⁻ detection in cancer cells: an integrated experimental and computational study. (PubMed, Anal Bioanal Chem)
    Both probes integrate a celecoxib ligand for COX-2 targeting with a naphthalimide fluorophore...MM/PBSA calculations revealed favorable binding enthalpies for both S1 (-80.05 ± 7.19 kcal/mol) and S2 (-83.76 ± 3.88 kcal/mol) with COX-2, confirming stable and specific complex formation. This integrated experimental and computational strategy yields highly sensitive and selective probes, positioning S1 and S2 as promising tools for studying cancer-related biomarkers at the cellular level.
    Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    |
    celecoxib oral
    10d
    Ferrostatin-1 attenuates sepsis-induced lung injury by inhibiting ferroptosis via activation of the SLC7A11/GSH/GPX4 signaling pathway. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci)
    In sepsis-induced lung injury, the ferroptosis-related SLC7A11/GSH/GPX4 signaling pathway is downregulated. Ferrostatin-1 activates this pathway and protects the lungs.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • GPX4 (Glutathione Peroxidase 4) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • FER (FER Tyrosine Kinase) • SLC7A11 (Solute Carrier Family 7 Member 11) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    |
    erastin
    11d
    Prostate Cancer: Dissecting Novel Immunosuppressive Mechanisms Through Context-Specific Transcriptomic Programs and MDSC Cells. (PubMed, Int J Mol Sci)
    Structural modeling uncovered a three-way junction and 3' triple helix in lncRNA. Collectively, these data suggest that circulating inflammatory rewiring is associated with checkpoint-rich suppressor expansion and tumor immune quiescence, outlining integrated myeloid- and RNA-directed strategies for cancer research.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • CD47 (CD47 Molecule) • CD73 (5'-Nucleotidase Ecto) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • IL17A (Interleukin 17A) • LGALS9 (Galectin 9) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • SIRPA (Signal Regulatory Protein Alpha)
    11d
    Neuroprotective Potential of Hericium erinaceus Through Modulation of Inflammatory Signaling in THP-1 Macrophages Under Low-Level Lead Exposure. (PubMed, Int J Mol Sci)
    MCP-1 secretion was fine-tuned toward control values, consistent with macrophage morphological changes, while IL-6 levels were increased. Overall, these findings indicate that Hericium erinaceus exerts immunomodulatory effects in microglia-like cells under low-level lead exposure, supporting its neuroprotective potential through modulation of neuroinflammatory signaling.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CCL2 (Chemokine (C-C motif) ligand 2)
    11d
    Anti-inflammatory activity and potential anti-inflammatory mechanisms of Artemisia scoparia essential oil. (PubMed, J Pharm Pharmacol)
    These findings suggest that ASEO has great potential as a natural anti-inflammatory agent, its key compositions and multiple anti-inflammatory mechanisms make it a promising candidate for further research and development for clinical applications.
    Journal
    |
    ER (Estrogen receptor) • TNFA (Tumor Necrosis Factor-Alpha) • EP300 (E1A binding protein p300) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • MPO (Myeloperoxidase) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    |
    dexamethasone
    12d
    Impact of bone metastasis on the prognosis of lung adenocarcinoma patients treated with third-generation EGFR-TKIs and the underlying mechanisms (PubMed, Zhonghua Yi Xue Za Zhi)
    Bone metastasis is an adverse prognostic factor for progression-free survival in lung adenocarcinoma patients treated with third-generation EGFR-TKIs. Bone metastasis lesions exhibit a distinct immunosuppressive tumor microenvironment in EGFR-mutant advanced lung adenocarcinoma, in which upregulation of immune regulatory genes in cancer cells and dysfunction of immune cells may constitute a potential mechanism underlying resistance to third-generation EGFR-TKIs.
    Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • IRF1 (Interferon Regulatory Factor 1) • SLC7A5 (Solute Carrier Family 7 Member 5) • CD55 (CD55 Molecule) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    |
    EGFR mutation
    13d
    Repurposing disulfiram for ALDH-positive NSCLC: Network-based inhibition of EGFR, COX-2, and MAPK1. (PubMed, J Mol Graph Model)
    These targets were found to bind DSF with very high affinity (7.45 -6.15 -6.65 kcal/mol, respectively) in comparison to reference inhibitors (Erlotinib, Celecoxib, Sorafenib). The article presents mechanistic support to the multi-target effect of DSF in ALDH + NSCLC through inhibition of EGFR, COX-2, and MAPK1, potent agents of stemness and resistance to drugs. It is believed that the reuse of DSF would be effective in treating NSCLC therapeutic resistance and promote its use in practice.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MAPK1 (Mitogen-activated protein kinase 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    |
    erlotinib • sorafenib • celecoxib oral
    14d
    Gene Expression Profiling to Unveil Novel Biomarkers for Early Diagnosis and Therapies for Breast Cancer. (PubMed, Curr Top Med Chem)
    The stability of the top three receptor-ligand complexes was validated through molecular dynamics simulations. Therefore, our findings could be a valuable resource for researchers and medical professionals, aiding in BC diagnosis and treatment.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CAV1 (Caveolin 1) • MIR155 (MicroRNA 155) • CD34 (CD34 molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD36 (thrombospondin receptor) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    |
    Lynparza (olaparib) • lapatinib • Verzenio (abemaciclib) • Tukysa (tucatinib)
    27d
    Dihydroartemisinin Promotes N1 Polarization of Tumor-Associated Neutrophils and Enhances Their Anti-Tumor Activity via Hub Gene Modulation. (PubMed, Pharmaceuticals (Basel))
    Functional assays demonstrated that DHA-treated cells exhibited increased secretion of TNF, IL1β, ROS, and PD-L1, accompanied by enhanced cytotoxic activity against hepatocellular carcinoma cells in a co-culture system. These findings reveal the molecular mechanisms underlying TAN polarization, and establish DHA as a potent immunomodulatory agent capable of reshaping TANs toward an anti-tumor phenotype.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • BCL2A1 (BCL2 Related Protein A1) • IL1B (Interleukin 1, beta) • CEACAM8 (CEA Cell Adhesion Molecule 8) • CXCL16 (C-X-C Motif Chemokine Ligand 16) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • SOCS3 (Suppressor Of Cytokine Signaling 3)
    29d
    COX-2 downregulation via G-quadruplex structure induction in the PTGS2-promoter region by mononuclear octahedral cobalt(III) Schiff base complex [CoL3] in colorectal cancer cells. (PubMed, Biochim Biophys Acta Gen Subj)
    Therefore, [CoL3] induces G-quadruplex formation in the promoter region of PTGS2, which ultimately inhibits protein expression of COX-2. This means that [CoL3] can be an effective agent for colorectal cancer treatment.
    Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    1m
    Research Progress of Cyclooxygenase-2 in Colorectal Adenomas. (PubMed, Cancer Biother Radiopharm)
    COX-2 is a critical early-event biomarker and therapeutic target in colorectal adenomas. Targeting the COX-2 pathway represents a viable strategy for prevention, although challenges regarding safety and personalized application remain.
    Review • Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    |
    celecoxib oral